Vanoxerine

Cat. No.: HY-13217A
CAS No.: 67469-69-6
Molecular Formula: C₂₈H₃₂F₂N₂O
Molecular Weight: 450.56
Target: Dopamine Transporter
Pathway: Neuronal Signaling
Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description
Vanoxerine (GBR-12909) is a competitive, potent, and highly selective dopamine reuptake inhibitor ($K_i=1$ nM). Vanoxerine (GBR-12909) binds to the target site on the dopamine transporter (DAT)\(^1\).

IC\(_{50}\) & Target
$K_i$: 1 nM (dopamine reuptake)\(^1\)

In Vitro
Vanoxerine (GBR-12909) inhibits the uptake of dopamine (DA), with an IC\(_{50}\) in the low nanomolar range, and is several-fold less potent as inhibitors of the uptake of noradrenaline and 5-HT\(^2\). Vanoxerine (GBR-12909) is also an oral, mixed ion channel blocker with IKr, INa, and L-type calcium channel activity\(^3\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo
Vanoxerine (GBR-12909) (2.5-20 mg/kg; i.p.) significantly increases the ambulatory activity\(^3\). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male mice (ddY strain at 6 weeks of age)\(^3\)
Dosage: 2.5, 5, 10, 20 mg/kg
Administration: Intraperitoneal injection
Result: The ambulatory activity of mice increased in a dose-dependent manner, with a maximal increase at 30 min after the administration.

CUSTOMER VALIDATION


See more customer validations on www.MedChemExpress.com

REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA